RASSF1 and lung cancer: Accumulating evidence suggests that aberrant promoter CpG island hypermethylation of SHOX2 and RASSF1A can serve as a diagnostic and prognostic biomarker for lung cancer, colorectal cancers, biliary tract cancers, and head and neck squamous cell carcinomas [18–21].